KLOW Blend vs TB-500
KLOW Blend (Multi-component research blend) and TB-500 (Actin-binding peptide fragment) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | KLOW Blend | TB-500 |
|---|---|---|
| Compound class | Multi-component research blend | Actin-binding peptide fragment |
| Research category | Healing & Recovery | Healing & Recovery |
| Length (amino acids) | Not documented | 7 amino acids |
| Molecular weight | Not documented | ~4921 Da (full-length thymosin beta-4); ~889 Da for the Ac-LKKTETQ fragment form |
| Half-life | Not documented | ~2-3 hours (elimination); tissue effects reported to persist for days |
| Origin | KLOW is a marketed multi-component research blend. It is typically described as combining GHK-Cu (copper tripeptide), KPV (an alpha-MSH fragment), and a BPC-157 / TB-500 combination. Exact composition can vary by supplier and it is not a naturally occurring substance. | TB-500 is a synthetic peptide commonly described as corresponding to the actin-binding domain (a short fragment, often the LKKTETQ region) of Thymosin Beta-4, a naturally occurring 43-amino-acid protein involved in actin regulation. TB-500 is produced synthetically and is not identical to full-length Thymosin Beta-4. |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How KLOW Blend works
As a blend, KLOW combines the documented properties of its components: GHK-Cu's copper-delivery and tissue-remodeling signaling, KPV's melanocortin-pathway anti-inflammatory activity, BPC-157's angiogenesis and growth-factor-related repair signaling, and TB-500's actin-regulation and cell-migration effects. These properties come from separate preclinical and cosmetic research; the combined formulation is not independently validated in controlled human trials.
How TB-500 works
Thymosin Beta-4 and its actin-binding fragment are studied for their ability to sequester G-actin and influence actin polymerization, which relates to cell migration. In preclinical models, this activity has been linked to cell migration, angiogenesis and tissue-repair processes. These mechanisms are drawn largely from animal and cell-culture research and are not established in controlled human trials for TB-500 itself.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
KLOW Blend
TB-500
What sets each apart
KLOW Blend
KLOW is a broader combination than two-component blends, pairing a copper cosmetic tripeptide and an anti-inflammatory MSH fragment with repair-focused peptides.
TB-500
TB-500 is defined by its actin-binding fragment identity, distinguishing it from BPC-157's growth-factor/angiogenesis focus and from copper tripeptides used cosmetically.
Documented together as a research blend
Cross-referenced for research context — not a usage or combination recommendation.
Frequently asked questions
What is the KLOW blend and what does the name mean?
KLOW is a four-component research blend most commonly composed of KPV, GHK-Cu, BPC-157, and TB-500. The name is generally described as KPV added to the GLOW blend, where GLOW is GHK-Cu + BPC-157 + TB-500. Exact composition and ratios vary by supplier, so the vial's COA is the authoritative source.
What is each component in KLOW contributing?
In research terms, GHK-Cu (copper tripeptide) is studied for gene-expression modulation and tissue remodeling, BPC-157 for angiogenic and nitric-oxide signaling, TB-500 for actin dynamics and cell migration, and KPV for anti-inflammatory NF-kB modulation. The blend is used to study combined tissue-repair and inflammation pathways rather than any single target. All such effects are preclinical.
What is a typical KLOW vial composition?
One commonly cited configuration is an 80 mg vial containing roughly 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500, and 10 mg KPV. Other vendors use different totals and ratios, so this should be verified against the specific product's certificate of analysis rather than assumed.
What is TB-500 and how does it relate to thymosin beta-4?
TB-500 is a research peptide associated with thymosin beta-4 (Tbeta4), a 43-amino-acid actin-binding regulatory peptide. The name TB-500 is used in the research-chemical market for both full-length thymosin beta-4 (MW ~4921 Da) and, in some references, the acetylated active fragment covering residues 17-23 (Ac-LKKTETQ). Buyers should check each vendor's COA, since what is shipped as 'TB-500' varies.
What is TB-500 studied for?
In animal models it is researched for tissue repair, wound healing, angiogenesis, and cell migration, largely through thymosin beta-4's role in sequestering G-actin and regulating the actin cytoskeleton. It has also been examined in cardiac and corneal repair models. Human clinical efficacy has not been established.
What does TB-500's half-life imply for research protocols?
Reported elimination half-life is roughly 2-3 hours, but downstream tissue effects are described as persisting for days through signaling cascades. Because of this, research protocols typically use infrequent dosing (e.g. a few times per week) rather than daily, loading over several weeks before a maintenance phase.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.